



LKT Laboratories, Inc.

Vemurafenib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID V1668

CAS No. 918504-65-1

Chemical Name N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide

Synonym PLX-4032, RG7204, RO5185426, Zelboraf

Formula C₂₃H₁₈ClF₂N₃O₃S

Formula Wt. 489.92

Melting Point


Purity ≥98%

Solubility Soluble in DMSO at 100 mg/mL;
very poorly soluble in ethanol;
very poorly soluble in water;
maximum solubility in plain
water is estimated to be about

Store Temp -20°C

Ship Temp Ambient

Description Vemurafenib is a first generation selective B-Raf inhibitor that has been approved for clinical use in treating unresectable or metastatic melanoma; it exhibits anticancer chemotherapeutic activity. Vemurafenib binds the ATP-binding domain of mutant (V600E) B-Raf, present in many cancer subtypes, to inhibit downstream MEK and ERK signaling. This compound inhibits MAPK signaling and cell cycle progression in cells expressing mutant (V600E) B-Raf, but may increase MAPK signaling in cells expressing WT B-Raf. Subjects undergoing treatment with Vemurafenib have potential to develop verrucal keratosis and cutaneous squamous cell carcinoma as side effects. Vemurafenib is currently under examination as a potential treatment against tumors expressing H-Ras mutations as well. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
V1668	10 mg	\$104.90
V1668	25 mg	\$209.80

References Anforth R, Blumetti TC, Clements A, et al. Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. Br J Dermatol. 2013 Jul 20. PMID: 23870055.

Beck D, Niessner H, Smalley KS, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 2013 Jan 29;6(260):ra7. PMID: 23362240.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.